Company / Operating Income
Avidity Biosciences, Inc. Operating Income History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$745.9M
FY2025
5-year range
-$745.9M / -$118.1M
FY2021-FY2025
Trend
-96.9%
vs FY2024
Sector context
#195 of 204
Health Care
What the data says
Among 204 Health Care companies, Avidity Biosciences, Inc. is in the bottom 4% for operating income. Operating Income has declined for 7 consecutive years, from -$10M in FY2018 to -$746M in FY2025.
Based on SEC 10-K filings.
-$746M in FY2025.
Declined from -$236M to -$746M over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 4% in Health CareTop 96% of 204This company -$745.9M Sector average $107.7M
▼
-792.5% below sector average
Key checks
Key Insights
- Avidity Biosciences, Inc.'s operating income has declined for 7 consecutive years.
- In FY2025, operating income decreased 96.9% year-over-year.
- Ranks #195 out of 204 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$745.9M | -96.9% |
| FY2024 | -$378.9M | -60.8% |
| FY2023 | -$235.6M | -31.7% |
| FY2022 | -$178.9M | -51.6% |
| FY2021 | -$118.1M | -166.6% |
| FY2020 | -$44.3M | -155.5% |
| FY2019 | -$17.3M | -65.1% |
| FY2018 | -$10.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026